Skip to content

Study · Animal study (in vivo) · rat · 2013

9 results

Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats.

Jandric I, Vrcic H, Jandric Balen M, Kolenc D, Brcic L, Radic B, Drmic D, Seiwerth S, Sikiric P

Medical science monitor basic research12 Mar 2013Cited by 19 (Europe PMC)

PMID23478678 (opens in a new tab)PMCIDPMC3940704 (opens in a new tab)DOI10.12659/msmbr.883828 (opens in a new tab)PepBankPUB-23478678
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with stress urinary incontinence after transabdominal urethrolysis, all BPC‑157 regimens counteracted the decrease of leak point pressure.

    In plain wordsIn rats with urine leakage after urethra surgery, BPC‑157 reduced the fall in leak point pressure.

    Peptide
    BPC-157
    Outcome
    IncreaseLeak point pressure (LPP) in TU rats
    Study

    ratn: not reported in source

    Stress urinary incontinence after transabdominal urethrolysis
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    10 µg/kg or 10 ng/kg intraperitoneally; 10 µg/kg in drinking water (0.16 µg/mL) · intraperitoneal or per-oral (drinking water) · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    All BPC 157 regimens counteracted decrease of LPP values in TU-rats
    1 context sentence
    Summary · context
    During a 7-day period, TU-rats and VD-rats (or healthy rats) received BPC 157, either (i) intraperitoneally, 10 µg/kg or 10 ng/kg, once daily (first administration 30 min after surgery, last 24 h before LPP-testing and sacrifice), or (ii) per-orally, 10 µg/kg in drinking water (0.16 µg/mL, 12 mL/rat/day).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with stress urinary incontinence after prolonged vaginal dilatation, all BPC‑157 regimens counteracted the decrease of leak point pressure.

    In plain wordsIn rats with urine leakage after vaginal stretching, BPC‑157 reduced the fall in leak point pressure.

    Peptide
    BPC-157
    Outcome
    IncreaseLeak point pressure (LPP) in VD rats
    Study

    ratn: not reported in source

    Stress urinary incontinence after prolonged vaginal dilatation
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    10 µg/kg or 10 ng/kg intraperitoneally; 10 µg/kg in drinking water (0.16 µg/mL) · intraperitoneal or per-oral (drinking water) · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    All BPC 157 regimens counteracted decrease of LPP values in TU-rats and VD-rats.
    1 context sentence
    Summary · context
    During a 7-day period, TU-rats and VD-rats (or healthy rats) received BPC 157, either (i) intraperitoneally, 10 µg/kg or 10 ng/kg, once daily (first administration 30 min after surgery, last 24 h before LPP-testing and sacrifice), or (ii) per-orally, 10 µg/kg in drinking water (0.16 µg/mL, 12 mL/rat/day).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In TU rats, BPC‑157 given intraperitoneally (microgram dose) or per-orally brought leak point pressure to the values seen in healthy rats.

    In plain wordsIn rats with urine leakage after urethra surgery, BPC‑157 brought leak point pressure back to the level of healthy rats.

    Peptide
    BPC-157
    Outcome
    IncreaseLPP reaching healthy-rat values in TU rats
    Study

    ratn: not reported in source

    Stress urinary incontinence after transabdominal urethrolysis
    Comparator
    Healthy rats
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    10 µg/kg or 10 ng/kg intraperitoneally; 10 µg/kg in drinking water (0.16 µg/mL) · intraperitoneal (10 µg/kg) or per-oral · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    BPC 157-TU rats (µg-intraperitoneally or per-orally)
    2 context sentences
    Summary · context
    reached LPP values originally noted in healthy rats.
    Summary · context
    During a 7-day period, TU-rats and VD-rats (or healthy rats) received BPC 157, either (i) intraperitoneally, 10 µg/kg or 10 ng/kg, once daily (first administration 30 min after surgery, last 24 h before LPP-testing and sacrifice), or (ii) per-orally, 10 µg/kg in drinking water (0.16 µg/mL, 12 mL/rat/day).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In VD rats, BPC‑157 given intraperitoneally (microgram dose) brought leak point pressure to the values seen in healthy rats.

    In plain wordsIn rats with urine leakage after vaginal stretching, BPC‑157 brought leak point pressure back to the level of healthy rats.

    Peptide
    BPC-157
    Outcome
    IncreaseLPP reaching healthy-rat values in VD rats
    Study

    ratn: not reported in source

    Stress urinary incontinence after prolonged vaginal dilatation
    Comparator
    Healthy rats
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    10 µg/kg or 10 ng/kg intraperitoneally; 10 µg/kg in drinking water (0.16 µg/mL) · intraperitoneal (10 µg/kg) · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    BPC 157-VD rats (µg intraperitoneally) reached LPP values originally noted in healthy rats.
    1 context sentence
    Summary · context
    During a 7-day period, TU-rats and VD-rats (or healthy rats) received BPC 157, either (i) intraperitoneally, 10 µg/kg or 10 ng/kg, once daily (first administration 30 min after surgery, last 24 h before LPP-testing and sacrifice), or (ii) per-orally, 10 µg/kg in drinking water (0.16 µg/mL, 12 mL/rat/day).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In healthy rats, BPC‑157 did not alter leak point pressure.

    In plain wordsIn healthy rats, BPC‑157 did not change leak point pressure.

    Peptide
    BPC-157
    Outcome
    No significant changeLPP in healthy rats
    Study

    ratn: not reported in source

    Healthy rats
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    10 µg/kg or 10 ng/kg intraperitoneally; 10 µg/kg in drinking water (0.16 µg/mL) · intraperitoneal or per-oral (drinking water) · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Conversely, in healthy rats, BPC 157 did not alter LPP.
    1 context sentence
    Summary · context
    During a 7-day period, TU-rats and VD-rats (or healthy rats) received BPC 157, either (i) intraperitoneally, 10 µg/kg or 10 ng/kg, once daily (first administration 30 min after surgery, last 24 h before LPP-testing and sacrifice), or (ii) per-orally, 10 µg/kg in drinking water (0.16 µg/mL, 12 mL/rat/day).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with stress urinary incontinence, BPC‑157 treatment gave higher desmin positivity within the urethral wall than in controls.

    In plain wordsIn rats with urine leakage, BPC‑157 treatment gave more of the muscle marker desmin in the urethral wall than in controls.

    Peptide
    BPC-157
    Outcome
    IncreaseDesmin positivity in urethral wall
    Study

    ratn: not reported in source

    SUI rat models (TU and VD)
    Comparator
    Controls
    Outcome group
    Muscle injury and repair · Kidney and urinary
    Studied dose
    10 µg/kg or 10 ng/kg intraperitoneally; 10 µg/kg in drinking water (0.16 µg/mL) · intraperitoneal or per-oral (drinking water) · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    higher desmin (delineates striated organization of skeletal muscle), smooth muscle actin, and CD34 (angiogenic marker) positivity within the urethral wall in BPC 157-treated rats vs. controls
    1 context sentence
    Summary · context
    During a 7-day period, TU-rats and VD-rats (or healthy rats) received BPC 157, either (i) intraperitoneally, 10 µg/kg or 10 ng/kg, once daily (first administration 30 min after surgery, last 24 h before LPP-testing and sacrifice), or (ii) per-orally, 10 µg/kg in drinking water (0.16 µg/mL, 12 mL/rat/day).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with stress urinary incontinence, BPC‑157 treatment gave higher smooth muscle actin positivity within the urethral wall than in controls.

    In plain wordsIn rats with urine leakage, BPC‑157 treatment gave more of the muscle marker smooth muscle actin in the urethral wall than in controls.

    Peptide
    BPC-157
    Outcome
    IncreaseSmooth muscle actin positivity in urethral wall
    Study

    ratn: not reported in source

    SUI rat models (TU and VD)
    Comparator
    Controls
    Outcome group
    Muscle injury and repair · Kidney and urinary
    Studied dose
    10 µg/kg or 10 ng/kg intraperitoneally; 10 µg/kg in drinking water (0.16 µg/mL) · intraperitoneal or per-oral (drinking water) · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    higher desmin (delineates striated organization of skeletal muscle), smooth muscle actin, and CD34 (angiogenic marker) positivity within the urethral wall in BPC 157-treated rats vs. controls
    1 context sentence
    Summary · context
    During a 7-day period, TU-rats and VD-rats (or healthy rats) received BPC 157, either (i) intraperitoneally, 10 µg/kg or 10 ng/kg, once daily (first administration 30 min after surgery, last 24 h before LPP-testing and sacrifice), or (ii) per-orally, 10 µg/kg in drinking water (0.16 µg/mL, 12 mL/rat/day).
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with stress urinary incontinence, BPC‑157 treatment gave higher CD34 positivity, a marker of new blood vessels, within the urethral wall than in controls.

    In plain wordsIn rats with urine leakage, BPC‑157 treatment gave more of the blood-vessel marker CD34 in the urethral wall than in controls.

    Peptide
    BPC-157
    Outcome
    IncreaseCD34 (angiogenic marker) positivity in urethral wall
    Study

    ratn: not reported in source

    SUI rat models (TU and VD)
    Comparator
    Controls
    Outcome group
    Muscle injury and repair · Kidney and urinary
    Studied dose
    10 µg/kg or 10 ng/kg intraperitoneally; 10 µg/kg in drinking water (0.16 µg/mL) · intraperitoneal or per-oral (drinking water) · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    higher desmin (delineates striated organization of skeletal muscle), smooth muscle actin, and CD34 (angiogenic marker) positivity within the urethral wall in BPC 157-treated rats vs. controls
    1 context sentence
    Summary · context
    During a 7-day period, TU-rats and VD-rats (or healthy rats) received BPC 157, either (i) intraperitoneally, 10 µg/kg or 10 ng/kg, once daily (first administration 30 min after surgery, last 24 h before LPP-testing and sacrifice), or (ii) per-orally, 10 µg/kg in drinking water (0.16 µg/mL, 12 mL/rat/day).
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats with stress urinary incontinence treated with BPC‑157, the overall muscle/connective tissue ratio was preserved.

    In plain wordsIn rats with urine leakage treated with BPC‑157, the balance of muscle and connective tissue in the urethral wall stayed preserved.

    Peptide
    BPC-157
    Outcome
    Not applicableMuscle/connective tissue ratio (Mallory's trichrome)
    Study

    ratn: not reported in source

    SUI rat models (TU and VD)
    Outcome group
    Muscle injury and repair · Kidney and urinary
    Studied dose
    10 µg/kg or 10 ng/kg intraperitoneally; 10 µg/kg in drinking water (0.16 µg/mL) · intraperitoneal or per-oral (drinking water) · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    as well as overall preserved muscle/connective tissue ratio assessed with Mallory's trichrome staining.
    1 context sentence
    Summary · context
    During a 7-day period, TU-rats and VD-rats (or healthy rats) received BPC 157, either (i) intraperitoneally, 10 µg/kg or 10 ng/kg, once daily (first administration 30 min after surgery, last 24 h before LPP-testing and sacrifice), or (ii) per-orally, 10 µg/kg in drinking water (0.16 µg/mL, 12 mL/rat/day).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.